Evaluation of relation between hepatic iron deposition and liver histopathology in patients with Chronic hepatitis c

Yıl 2011, , 27 - 32, 01.03.2011

Mustafa Tanrıverdi Mustafa Namıduru İlkay Karaoğlan Ediz Tutar Emine Sibel Namıduru Gülşen Özkan Tanrıverdi

https://doi.org/10.5505/sakaryamj.2011.29494

Öz

Objective: The aim of this study is to search the effects of hepatic iron deposition for the liver fibrosis and inflammation in patients with chronic hepatitis C (CHC).Materials and Methods: The records of 70 patients with CHC who had not previously been treated with antiviral therapy were reviewed retrospectively. The liver biopsies of these patients have been scored in terms of inflammation and fibrosis with the method of modified ISHAK by only one patholog. Preparations were prepared from these liver biopsies were stained with Persl' Prussian blue. Hepatic iron deposition was evaulated using the method of semicantitative modified MacSween by the same pathology.Results: In the histopathological evaluation of liver biopsy samples, increased hepatic iron deposition has been found in 25 patients (38.5%). A significant relation has been found between increased hepatic iron deposition and histological activity index (HAI) (p=0.001), but not found fibrosis degree (p>0.05). Fibrosis and HAI degrees were higher in patients with severe-moderate hepatic iron deposition.In conclusion: Increased hepatic iron deposition may be associated with severe hepatic fibrosis and inflammation in patients with chronic hepatitis C.

Anahtar Kelimeler

Chronic hepatitis C, Hepatic iron deposition; Hepatic fibrosis

Kronik hepatit c hastalarında karaciğer demir birikimi ile karaciğer histopatolojisi arasındaki ilişkinin değerlendirilmesi

Öz

Amaç: Kronik hepatit C (KHC) hastalarında karaciğer demir birikiminin karaciğer fibrozisi ve enflamasyonu üzerine etkilerini araştırmak.Gereç ve Yöntemler: Daha önce antiviral tedavi almamış 70 KHC'li hastanın kayıtları retrospektif olarak tarandı. Bu hastaların karaciğer biyopsileri tek bir patolog tarafından modifiye ISHAK yöntemiyle enflamasyon ve fibrozis açısından skorlandı. Bu karaciğer biyopsilerinden tekrar hazırlanan preparatlar Persl' Prusya mavisi ile boyandı. Karaciğerdeki demir miktarı semikantitatif Modifiye MacSween karaciğer demir yükü evrelemesi kullanılarak aynı patolog tarafından değerlendirildi.Bulgular: Karaciğer biyopsi örneklerinin histopatolojik olarak incelenmesinde 25 hastada (% 35.7) artmış karaciğer demir birikimi tespit edildi. Artmış karaciğer demir birikimi ile histolojik aktivite indeksi (HAI) arasında anlamlı bir ilişki varken (p=0.001), fibrozis ile anlamlı ilişki saptanmadı (p>0.05). Ağır-orta artmış karaciğer demir birikimi olan olgularda fibrozis ve HAI dereceleri daha ileri idi.Sonuç: KHC'li hastalarda, artmış karaciğer demir birikimi ilerlemiş karaciğer fibrozisi ve enflamasyonu ile ilişkili olabilir.

Anahtar Kelimeler

Kronik hepatit C, Karaciğer demir birikimi; Hepatik fibrozis

Kaynakça

• Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29:74- 81.
• Mıstık R. Turkiye’de viral hepatit epidemiyolojisi – Yayınların irdelenmesi. In: Tabak F, Balık İ, Tekeli E, eds. Viral Hepatit 2007. Ankara: Viral Hepatitle Savaşım Derneği, 2007:10-50
• Riggio O, Montagnese F, Fiore P, Folino S, Giambartolomei S, Gandin C, et al. L. Iron overload in patients with chronic viral hepatitis: how common is it? Am J Gastroenterol. 1997;92:1298- 1301.
• Atanasiu V, Manolescu B, Stoian I. Hepcidin-central regulator of iron metabolism. Eur J Haematol. 2007;78:1-10.
• Hershko C, Peto TE. Non-transferrin plasma iron. Br J Haematol. 1987;66:149-51.
• Hershko C. Mechanism of iron toxicity and its possible role in red cell membrane damage. Sem Hematol. 1989;26:277-285.
• Lok ASF, Mcmahon BJ. AASLD practise guidlines. Hepatology. 2009;50:1-36.
• Ishak KG, Baptista A, Bianchi L. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696-699.
• MacSween RNM, Burt AD, Portman BC, Ihsak KG, Scheuer PJ, Anthony PP. Pathology of the Liver. 4th ed. London: Churchill Livingstone, 2002.
• Lo Re III V, Kostman JR. Management of chronic hepatitis C. Postgrad Med J. 2005;81:376-82.
• Di Bisceglie AM, Axiotis CA, Hoofnagle JH, Bacon BR. Measurements of iron status in patients with chronic hepatitis. Gastroenterology. 1992;102:2108-2113.
• Metwally MA, Zein CO, Zein NN. Clinical significance of hepatic iron deposition and serum iron values in patients with chronic hepatitis C infection. Am J Gastroenterol. 2004;99:286-291.
• Tsung-Jung L, Li-Ying L, Shyr-Yi L, Chih-Lin L, Ting-An C. Influence of iron on the severity of hepatic fibrosis in patients with chronic hepatitis C. World J Gastroenterol. 2006;12:4897-4901
• D’souza RFC, Feakıns R, Mears L, Sabın CA, FosterGR. Relationship between serum ferritin, hepatic iron staining, diabetes mellitus and fibrosis progression in patients with chronic hepatitis C. Aliment Pharmacol Ther. 2005;21:519-524.
• Arora S, O’Brian C, Zeuzem S. Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40KD) plus ribavirin: impact on health-related quality of life. J Gastroenterol Hepatol. 2006;21:406-12.
• Bonkovsky HL, Banner BF, Rothman AL. Iron and chronic viral hepatitis. Hepatology. 1997;25:759-768.